Researchers in Germany secured a €1.1 million grant from ForTra gGmbH for Research Transfer in September 2026 to advance a transdermal drug patch for multiple sclerosis. Developed at Johannes Gutenberg University Mainz, the patch uses low-dose theophylline to activate histone deacetylase 2 and promote myelin repair.
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease characterized by the immune system mistakenly attacking myelin, the protective fatty sheath surrounding nerve fibers in the brain and spinal cord. While standard disease-modifying therapies work by reducing inflammation and preventing disease flares, they cannot actively repair already damaged myelin. A team of scientists in Germany is now bridging that therapeutic gap by developing a transdermal delivery system designed to stimulate remyelination, pushing an experimental drug formulation closer to its initial human trials.
In Plain English: The Clinical Takeaway
- What is being tested? A skin patch that continuously delivers low doses of theophylline—a traditional asthma medication—directly through the skin to stimulate nerve repair mechanisms.
- Why does it matter? Current MS treatments slow disease progression and control immune attacks, but no approved treatment is specifically designed to actively rebuild damaged myelin sheaths.
- What is the next step? Funded by a €1.1 million grant awarded on September 1, 2026, the project will move into Good Manufacturing Practice (GMP) production followed by a Phase 1 clinical trial in healthy volunteers.
Targeting Myelin Repair Through HDAC2 Activation
The scientific foundation of the transdermal patch rests on more than two decades of investigation into the mechanisms by which the nervous system repairs damaged myelin. Claire Jacob, PhD, a professor at Johannes Gutenberg University Mainz (JGU), led the laboratory work identifying the epigenetically active enzyme histone deacetylase 2 (HDAC2) as a critical driver of this repair process. When researchers increase HDAC2 activity, molecular processes involved in remyelination are stimulated.
To engage this biological target without exposing patients to the side effects associated with higher doses, the research group turned to theophylline. Long utilized as a bronchodilator to relax airway muscles in respiratory conditions like asthma, low-dose theophylline successfully elevated HDAC2 activity in preclinical mouse models. According to public disclosures from JGU, the project previously received €140,000 in early support from the Mainz Science Foundation to prove this concept in animals.
Transdermal Delivery and Pharmaceutical Engineering
Delivering a precise, low therapeutic dose of theophylline consistently over time required specialized engineering. Professor Peter Langguth, PhD, also at JGU, collaborated with the cellular biology team to design a skin patch that administers the active compound continuously across several days. This transdermal approach bypasses oral dosing fluctuations, keeping the drug concentration at the precise low threshold necessary to stimulate HDAC2.
The recent financial injection—totaling €1.1 million (nearly $1.3 million)—comes from ForTra gGmbH for Research Transfer, a nonprofit subsidiary of the Else Kröner-Fresenius Foundation. This capital enables the transition from university laboratories to a German manufacturer. The product will undergo optimization to satisfy Good Manufacturing Practice (GMP) standards, a set of quality control requirements required for any medicinal product entering human clinical investigation.
Clinical Trial Roadmap and Regulatory Expectations
Once large-scale GMP production is finalized, the patch will be evaluated at the Mainz University Medical Center in a Phase 1 clinical trial involving healthy volunteers. Project disclosures confirm that this initial human study will primarily assess basic metrics, including patch adhesion, general tolerability, and how effectively the drug passes through the skin. Because the primary safety trial utilizes healthy participants rather than MS patients, it will not measure myelin regeneration.
If the experimental treatment clears this initial human safety hurdle, the research group intends to design a multicenter Phase 2 trial involving diagnosed multiple sclerosis patients in Germany. Securing additional funding will be necessary to launch that subsequent phase, which would provide the first opportunity to determine whether targeted theophylline delivery can promote myelin rebuilding in humans.
Contraindications & When to Consult a Doctor
Patients diagnosed with multiple sclerosis must not attempt to self-administer oral theophylline or replicate transdermal experiments outside of a formal clinical trial setting. Anyone experiencing worsening neurological deficits, new sensory symptoms, or unexpected gait changes should immediately consult their treating neurologist or healthcare professional. Approved disease-modifying therapies remain the gold standard of care, and alterations to existing treatment regimens should only occur under direct medical supervision.
Outlook
The progression of the theophylline skin patch toward clinical evaluation represents a step forward in neurodegenerative research. By focusing on remyelination rather than purely immunosuppressive mechanisms, the Mainz research team addresses an unmet need in neuropharmacology. The transition into manufacturing marks a milestone for the MS research community.
References
- Multiple Sclerosis News Today. “€1.1M grant moves skin patch for MS closer to first human trial.” Published September 2026.
- Archynewsy. “New MS Drug Patch for Myelin Repair Moves to Clinical Trials.” Published September 2026.
- Johannes Gutenberg University Mainz. Institutional Research Announcements on Transdermal Theophylline Development, 2026.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified physician regarding any questions about a medical condition.
